PAVE 0.28ZWS.TO -0.03VMO.TO 0.53ZAP 0.15CAT 1.97AMZN -2.48GL 0.33DAL -1.96
Stryker Corp. (SYK)

NYSE:SYK

Stryker Corp. (SYK)

339.21
-1.88 (0.55%)
as of Aug 14, 2026, 8:00:00 pm Market Open.
260 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 15, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Stryker Corp. (SYK) remains a leading player in the medical device sector, particularly in orthopedics, holding a significant market share in the U.S. With its robust robotics platform and the increasing demand driven by aging demographics, particularly in hip and knee replacements, the company shows strong potential for recovery from recent challenges, including a cybersecurity attack. Despite recent weaknesses in the broader medtech industry, many analysts express optimism around SYK's growth trajectory, with expectations of revenue and earnings per share advancing in the coming years. Additionally, Stryker's solid relationships with healthcare providers and a sticky business model (where surgeons tend to stick with suppliers) position it well for sustained success. However, some experts caution that while the stock may have long-term merits, the current investment climate may not be optimal.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
ZIM, ZIM
PAST TOP PICK

Stryker Corp.(SYK)

Feb 03, 2022
(A Top Pick Feb 11/21, Up 4%) Came under pressure, as it's classified higher growth. Still likes their business, as everything in those operating rooms is made by Stryker. Main area of growth is robotic surgery. Wage and cost inflation. Sees perhaps slower capex. Very well run.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$253.33

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Nov 02, 2021
73% of their business is in the US plus 21% in developed markets and 6% in emerging, so there's more EM growth to come. Also, elective surgeries were put on hold during Covid, so there's a big backlog to come. Also aging demographics are a tailwind. Also, surgeons remain loyal to their surgical products. (Analysts’ price target is $284.10)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$269.70

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Oct 22, 2021
(A Top Pick Oct 02/20, Up 34%) This was recommend before vaccines. This company benefits from elective surgery. These surgeries were not happening then. Expects them to report record earnings in 2021. Better days lie a head. Benefits from the aging population. Has intimate relationships with doctors. It is also a platform that is good at acquiring businesses.
Photo of Barry SchwartzBarry Schwartz
Owned
Unlock Rating
$275.73

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Sep 30, 2021
(A Top Pick Sep 14/20, Up 32%) Medical devices are an important place to be. Good acquisition right before the pandemic. Demographic play. Pandemic backlog should ease and improve revenues. Good opportunity globally for next few years.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$266.16

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Aug 24, 2021
Has long held this. They produce medical devices for hips, knees and spines. The sector fell off during lockdowns due to no or few elective surgeries, however that is rebounding. Also, this is a demographic play as the population ages and needs such surgeries. Also, doctors stay loyal to a brand of medical devices. Trades at 25x earnings and has $3.7 billion in free cash. (Analysts’ price target is $288.43)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$271.21

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Jul 22, 2021
(A Top Pick Jul 21/20, Up 37%) Great business. Demographic tailwind. User loyalty. Pandemic surgery slowdown created a backlog that's coming online now. Good free cashflow growth can be used to pay down debt and make acquisitions. Good upside for next several years.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$256.87

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Jun 17, 2021
(A Top Pick Jun 26/20, Up 50%) Huge backlog of surgeries due to Covid. Really improves quality of life. Terrific brand loyalty. Good demographic play. More upside. Will keep raising dividend, buying back shares, making acquisitions.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$259.17

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Jun 07, 2021
With the opening of elective surgeries, it will start to pickup. The aging population will benefit them. They are head and shoulders above their peers.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$249.10

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

May 12, 2021
Rough time, as elective surgeries on hold during Covid. Good growth. Loyal users of products, good demographics. Acquisition of Wright Medical will work out well. Yield is 1.02%. (Analysts’ price target is $270.28)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$244.76

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Apr 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$265.56

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Apr 06, 2021
They produce medical devices for hips, knees, hands and ankles. Elective surgeries are coming back after pandemic lockdowns. SYK's medical products reduce medical stays and drug use, which benefits American hospitals and patients. Again demographics are another tailwind. He expects good growth. SYK holds a lot of fresh cash to pay debt and the dividend. (Analysts’ price target is $251.00)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$248.48

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Mar 29, 2021
It has not done that well through the pandemic. Their appliances are used on an elective basis, so their installation got canceled by hospitals. Sales are expected to grow by 19% this year. (Analysts’ price target is $251.00)
Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$242.03

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Feb 11, 2021
(A Top Pick Jan 17/20, Up 16%) Medical devices and robotic-assisted surgery. Elective surgeries have resumed from last quarter.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$243.70

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Feb 11, 2021
Great growth in robotics surgery. Uptick in elective surgery. Stands to benefit from pent-up demand as we return to normal. Likes it short- and medium-term. Yield is 1.03% (Analysts’ price target is $249.12)
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$243.70

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Dec 24, 2020
(A Top Pick Dec 19/19, Up 15%) Medical healthcare. Great demographics, knee, hip, and spine replacements. Important to quality of life. Stock fell in March when elective surgeries were cancelled, but they're coming back. Would buy it here.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$237.06

Stock price when the opinion was issued

$339.21

As of Aug 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 61 to 75 of 174 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

META -5.12$589.85
NVDA -0.14$225.16
ORCL -5.7$150.52
VEQT.TO -0.23$62.79
VBAL.TO -0.17$40.08

Today's Top Picks

PAVE 0.28$58.59
ZWS.TO -0.03$22.23
VMO.TO 0.53$96.97
ZAP 0.15$33.15
CAT 1.97$856.57

Popular Articles

Latest Sell Signals

QMAX.TO -0.22$25.53
CDZ.TO -0.01$46.94
VFV.TO -1.06$191.64
HTA.TO -0.14$22.93
ZEB.TO 0.38$78.29

Most Recent Experts

Bill Baruch, Founder, Blue Line Capital

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like